Euthyroid Sick Syndrome in Patients With COVID-19

Runmei Zou1†, Chenfang Wu2†, Siye Zhang2, Guyi Wang2, Quan Zhang3, Bo Yu2, Ying Wu2, Haiyun Dong2, Guobao Wu2, Shangjie Wu4 and Yanjun Zhong2*

1 Children’s Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China, 2 Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China, 3 Critical Care Medicine, The First Hospital of Changsha, Changsha, China, 4 Department of Respiratory, The Second Xiangya Hospital, Central South University, Changsha, China

Background: Coronavirus disease 2019 (COVID-19) has been shown to affect almost every organ throughout the body. However, it is not clear whether the thyroid gland is impaired in COVID-19 patients. Euthyroid sick syndrome (ESS) is usually associated with the disease severity and deterioration prognosis in critical illness. In this study, the thyroid function of COVID-19 patients was assessed and factors associated with outcomes were analyzed to determine the potential predictive value of ESS.

Methods: Clinical and laboratory data of COVID-19 patients with or without ESS in Changsha, China, were collected and analyzed on admission. Kaplan-Meier curve and cox regression model were utilized to determine the correlation between ESS and the endpoints. Subsequently, a receiver operating characteristic (ROC) curve was plotted to evaluate the predictive performances of FT3 and C-reactive protein (CRP) in the disease severity.

Results: Forty-one (27.52%) cases of COVID-19 patients diagnosed with ESS. ESS patients had higher proportions of fever, shortness of breath, hypertension, diabetes, and severe events than those of non-ESS patients. The levels of erythrocyte sedimentation rate and C-reactive protein, and the positive rate of procalcitonin were significantly higher, whereas the lymphocyte count was apparently lower in ESS patients than in non-ESS patients. The regression analysis showed that ESS was significantly associated with the disease severity of COVID-19 (HR = 2.515, 95% CI: 1.050–6.026, P = 0.039). The areas under the curve (AUCs) for predicting the severe disease were [0.809 (95% CI 0.727–0.892), P < 0.001] and [0.792 (95% CI 0.689–0.895), P < 0.001] for FT3 and CRP, respectively.

Conclusion: ESS was significantly associated with the disease severity and inflammatory parameters in COVID-19 patients.

Keywords: Coronavirus Disease 2019 (COVID-19), euthyroid sick syndrome, thyroid function, disease severity, C-reactive protein
INTRODUCTION

Coronavirus Disease 2019 (COVID-19) is an infectious disease which causes severe respiratory illness. It was first reported in Wuhan, China, in December 2019 (1–3). It has spread widely around the world and been declared a pandemic by the World Health Organization (WHO) on March 11, 2020. As of August 28, over 24,000,000 cases and 800,000 deaths have been identified worldwide (4). The etiological agent of COVID-19 has been confirmed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (5).

COVID-19 can impair almost any structure in the human body from the brain to the toes, including lungs, liver, heart, kidney, brain, gut, etc. (6). The thyroid gland is a neuroendocrine organ which plays an important role in regulating immunity and metabolism. Whether the thyroid gland is affected by SARS-CoV-2 remains unclear. An identity match of more than 85% has been identified between SARS-CoV-2 and a bat SARS-like CoV genome published previously (7). A study composed of 48 SARS patients found that 93.7% patients had a low serum level of triiodothyronine (T3) (8). During acute illness, changes in the serum levels of thyroid hormones have been depicted which represent a condition known as euthyroid sick syndrome (ESS). ESS is characterized by a decreased level of serum T3 and/or thyroxine (T4) without an increased secretion of thyroid-stimulating hormone (TSH) (9). ESS is the physiologic adaptation and pathologic response to acute disease, occurring in the fasting state in healthy individuals, as well as in the context of infection, trauma, myocardial infarction, and malignancy (10). Previous studies suggested that thyroid hormone levels, especially low serum levels of free T3 (FT3), are usually associated with the disease severity and deterioration prognosis in critical illness (11, 12).

In this study, we assessed the thyroid function in patients with COVID-19 and analyzed the related factors to determine the potential value of ESS in predicting the disease severity. We found that COVID-19 patients with ESS had a higher risk of severe events than non-ESS patients. Besides, ESS was an independent risk factor for the severe event in COVID-19 patients. ESS also displayed a potent correlation with the inflammatory parameters.

METHODS

Study Design and Participants
This was a retrospective cohort study. The study was approved by the institutional ethics board of the second Xiangya Hospital of Central South University (No. 2020001). Laboratory-confirmed COVID-19 patients (aged 19–84 years old) admitted to Public Health Treatment Center of Changsha, China from January 17 to March 14, 2020, were enrolled. Patients with underlying primary thyroid disease, history of chemotherapy or radiotherapy in the last 6 months, suspicion of underlying hypothalamic or pituitary disease were excluded. ESS was described as serum FT3 <2.3 pg/ml with low or normal levels of TSH. Patients were divided into two groups according to serum FT3 values: ESS group and non-ESS group.

Data Collection
Two members of our team carefully gathered and individually reviewed the medical records of patients. Detailed information on demographic data, clinical symptoms, underlying comorbidities, medical history, laboratory parameters, and chest computed tomographic (CT) scans were checked and extracted. Blood samples were drawn from the patients on their first day of the hospitalization.

Endpoints
The primary endpoint of our study was the severe event. The second endpoints were the rates of noninvasive and invasive ventilation, mortality, virus shedding time, and length of hospital stay. We used one of the following criteria to determine the severe event of COVID-19: 1) respiratory rate ≥30/min; 2) oxygen saturation ≤93%; 3) PaO2/FiO2 ≤300 mmHg; 4) progression of lung lesions exceeding 50% within 24–48 h; 5) mechanical ventilation was implemented; 6) shock; 7) intensive care unit admission (13). The virus shedding time was defined as the time from illness onset (the day of diagnosis for asymptomatic patients) to the first negative samples without any positive sample thereafter.

Statistical Analysis
Continuous variables in our study were expressed as the median with inter quartile range (IQR) for data not following normal distribution and analyzed using the Mann-Whitney U test. Categorical data were described using frequencies and percentages. The χ2 test or Fisher’s exact test was used to compare the differences of the categorical variables. The Kaplan-Meier (KM) curve and cox proportional hazard regression models were applied to determine the association between ESS and the endpoints, with the hazards ratio (HR) and 95% confidence interval (95% CI) being reported. Finally, a receiver operating characteristic (ROC) curve was established to evaluate the predictive performances of FT3 and C-reactive protein (CRP) in the disease severity of COVID-19.

RESULTS
A total of 149 COVID-19 patients were enrolled in this study, of whom 41 (27.52%) cases were diagnosed with ESS. Out of these, 14 (34.15%) were males. The median age was 58 (IQR: 50–66) years old. The most common symptoms in the ESS group were fever [39 (95.12%)], fatigue [18 (43.90%)], cough [36 (87.80%)], shortness of breath [25 (60.98%)], expectoration [20 (48.78%)], and anorexia [21 (51.22%)]. Hypertension [10 (24.39%)] and diabetes [7 (17.07%)] were the most common comorbidities (Table 1).

Compared with non-ESS patients, patients with ESS were older [58 years (IQR: 50–66) vs 41 years (IQR: 31–65), P < 0.001] and exhibited a female dominance (65.85% vs 47.22%, P = 0.042).
Furthermore, patients with ESS tended to have a higher prevalence of fever and shortness of breath compared to non-ESS patients (95.12% vs 67.59%, *P* = 0.001; 60.98% vs 24.07%, *P* < 0.001, respectively). The occurrences of hypertension and diabetes were higher in ESS patients than those in non-ESS patients (24.39% vs 6.48%, *P* = 0.005; 17.07% vs 2.78%, *P* = 0.006, respectively) (Table 1).

| Symptom                  | ESS group (n = 41) | Non-ESS group (n = 108) | All patients (n = 149) | P value |
|--------------------------|--------------------|-------------------------|------------------------|---------|
| Fever (n, %)             | 39 (95.12)         | 73 (67.59)              | 112 (75.17)            | 0.001*  |
| Fatigue (n, %)           | 18 (43.90)         | 43 (39.81)              | 61 (40.94)             | 0.650   |
| Cough (n, %)             | 36 (87.80)         | 88 (81.48)              | 124 (83.22)            | 0.356   |
| Shortness of breath (n, %) | 25 (60.98)         | 26 (24.07)              | 51 (34.23)             | <0.001* |
| Expectoration (n, %)     | 20 (48.78)         | 49 (45.37)              | 69 (46.31)             | 0.709   |
| Hemoptyosis (n, %)       | 3 (7.32)           | 2 (1.85)                | 5 (3.36)               | 0.128   |
| Pharyngalgia (n, %)      | 6 (14.63)          | 21 (19.44)              | 27 (18.12)             | 0.496   |
| Vomiting (n, %)          | 4 (9.76)           | 12 (11.11)              | 16 (10.74)             | 1.000   |
| Diarrhea (n, %)          | 8 (19.51)          | 24 (22.22)              | 32 (21.48)             | 0.719   |
| Abdominal pain (n, %)    | 3 (7.32)           | 2 (1.85)                | 5 (3.36)               | 0.128   |
| Nausea (n, %)            | 5 (12.20)          | 12 (11.11)              | 17 (11.41)             | 1.000   |
| Anorexia (n, %)          | 21 (51.22)         | 47 (43.52)              | 88 (56.44)             | 0.399   |
| Myalgia (n, %)           | 3 (7.32)           | 11 (10.19)              | 14 (9.40)              | 0.825   |
| Chill (n, %)             | 8 (19.51)          | 12 (11.11)              | 20 (13.42)             | 0.179   |
| Dizziness (n, %)         | 7 (17.07)          | 12 (11.11)              | 19 (12.75)             | 0.350   |
| Headache (n, %)          | 7 (17.07)          | 16 (14.81)              | 23 (15.44)             | 0.733   |

*means a significant difference; ESS, euthyroid sick syndrome; M, median; IQR, inter quartile range; y, years.

Table 1: Baseline characteristics of patients with ESS and non-ESS.

Diabetes (n, %) | 7 (17.07) | 10 (6.71) | 0.006* |

Chronic liver disease (n, %) | 1 (2.44) | 6 (4.70) | 0.712 |

The associations between ESS and the outcomes of COVID-19 patients were presented in Table 3. COVID-19 patients with ESS had a significantly higher prevalence of severe events compared with those without ESS (log-rank *P* < 0.001, Figure 1). The results of cox regression analysis showed that both ESS (HR = 2.515, 95% CI: 1.050–6.026, *P* = 0.039), and CRP (HR = 1.031, 95% CI: 1.015–1.046, *P* < 0.001) were independent risk factors for the disease severity (Table 4).

Table 2: Comorbidities.

DISCUSSION

In the present study, we identified 41 (27.52%) COVID-19 patients with ESS. We compared the clinical characteristics between ESS and non-ESS patients and analyzed factors related to the disease severity of patients with COVID-19. The results demonstrated that ESS patients had a higher prevalence of severe events than non-ESS patients, which was consistent with the severity of symptoms and elevated inflammatory markers. The cox regression model suggested that ESS is an independent risk factor for the severity of COVID-19.

Previous studies demonstrated that a decreased level of FT3 was a prognostic indicator of critical disease, which was associated with all-cause mortality, especially in the intensive care unit.
A study consisting of 503 patients diagnosed with community-acquired pneumonia reported that ESS is an independent risk factor for the 30-day mortality (19). The pathophysiological process of ESS involved in the induction of type III deiodinase and decrease of type I deiodinase, which resulted in the increased conversion of T4 to rT3 instead of T3 (9). Furthermore, the HPT axis was suppressed under pathological conditions, contributing to the decreased secretion of TSH (20). This pathophysiological mechanism also involved the binding of thyroid hormone to plasma protein, transport of thyroid hormone in peripheral tissues, and the hormone receptor activity (10).

### TABLE 2 | Laboratory findings of patients with ESS and non-ESS.

| Test                           | ESS group (n = 41) | Non-ESS group (n = 108) | All patients (n = 149) | P value |
|--------------------------------|-------------------|-------------------------|------------------------|---------|
| WBC, ×10^9/L, M (IQR)          | 4.62 (3.38, 6.15) | 4.67 (3.68, 5.98)       | 4.63 (3.60, 6.03)      | 0.708   |
| Lymphocyte count, ×10^9/L, M (IQR) | 0.91 (0.59, 1.13) | 1.27 (0.91, 1.70)       | 1.13 (0.83, 1.52)      | <0.001* |
| T3, nmol/L, M (IQR)            | 1.01 (0.81, 1.10) | 1.47 (1.35, 1.68)       | 1.39 (1.11, 1.59)      | <0.001* |
| T4, nmol/L, M (IQR)            | 106.30 (89.38, 119.09) | 121.98 (107.78, 136.13) | 118.80 (100.67, 131.15) | <0.001* |
| FT4, pmol/L, M (IQR)           | 14.47 (12.72, 17.18) | 16.08 (13.43, 18.91)   | 15.80 (13.35, 18.11)   | 0.006*  |
| TSH, uIU/ml, M (IQR)           | 1.36 (1.01, 2.28) | 1.74 (1.13, 2.77)       | 1.63 (1.07, 2.56)      | 0.065   |
| ESR, mm/h, M (IQR)             | 66.5 (43, 82.5)   | 35 (15, 60)             | 46 (21.5, 68.5)        | <0.001* |
| CRP, mg/L, M (IQR)             | 38.99 (19.05, 60.96) | 11.26 (2.92, 22.88)    | 16.07 (4.14, 34.07)    | <0.001* |
| PCT ≥0.05 ng/ml, (n, %)         | 22 (53.66)        | 32 (29.63)              | 54 (36.24)             | 0.006*  |
| ALT, U/L, M (IQR)              | 18.95 (13.37, 28.75) | 19.72 (14.11, 26.41)   | 19.08 (13.75, 26.44)   | 0.973   |
| AST, U/L, M (IQR)              | 25.05 (21.31, 34.82) | 23.84 (18.85, 29.19)   | 23.97 (19.38, 30.47)   | 0.098   |
| Tbil, μmol/L, M (IQR)          | 11.14 (7.73, 14.59) | 10.29 (8.20, 14.82)    | 10.60 (8.08, 14.68)    | 0.784   |
| Scr, mmol/L, M (IQR)           | 54.91 (37.67, 65.55) | 50.51 (41.05, 65.66)   | 51.11 (40.74, 65.65)   | 0.883   |
| CK, U/L, M (IQR)               | 75.90 (50.10, 139.10) | 68.25 (44.38, 105.63)  | 68.70 (45.40, 111.40)  | 0.321   |
| CK-MB, M (IQR)                 | 11.00 (6.35, 13.95) | 9.50 (6.10, 12.30)     | 10.00 (6.10, 12.99)    | 0.320   |
| Chest CT positive rate (n, %)   | 41 (100.00)        | 101 (93.52)            | 142 (95.30)            | 0.216   |

*means a significant difference; ESS, euthyroid sick syndrome; M, median; IQR, inter quartile range; WBC, white blood cell count; T3, triiodothyronine; T4, thyroxine; FT4, free thyroxine; TSH, stimulating hormone; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCT, procalcitonin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Tbil, total bilirubin; Scr, serum creatinine; CK, creatine kinase; CK-MB, creatine kinase isoenzyme.

### TABLE 3 | Outcomes of patients with ESS and non-ESS.

| Outcome                        | ESS group (n = 41) | Non-ESS group (n = 108) | All patients (n = 149) | P value |
|--------------------------------|-------------------|-------------------------|------------------------|---------|
| Severe event (n, %)             | 15 (36.59)        | 11 (10.19)              | 26 (17.45)             | <0.001* |
| Noninvasive ventilator (n, %)   | 1 (2.44)          | 2 (1.85)                | 3 (2.01)               | 1.000   |
| Invasive ventilator (n, %)      | 1 (2.44)          | 1 (0.93)                | 2 (1.34)               | 0.476   |
| Mortality (n, %)                | 0 (0.00)          | 1 (0.93)                | 1 (0.67)               | 1.000   |
| Virus shedding time (days, IQR) | 19 (14, 23.5)     | 17 (13, 24)             | 17.50 (13, 24)         | 0.670   |
| Length of hospital stay (days, IQR) | 17 (12, 25)     | 15 (11, 23)             | 15.5 (11, 24.75)       | 0.345   |

*means a significant difference; ESS, euthyroid sick syndrome; IQR, inter quartile range.

![FIGURE 1](image1.png) | The time-dependent risk of reaching to the severe events.
In COVID-19 patients, ESS may be directly caused by infection of thyroid cells with SARS-CoV-2. Despite the fact that no article on the involvement of the thyroid gland in COVID-19 patients has been published, varying degrees of damage to the thyroid gland were confirmed in SARS patients back in 2007 (21). Meanwhile, the patients with COVID-19 had lower serum TSH and TT3 levels than healthy controls and non-COVID-19 pneumonia patients (19). Angiotensin-converting enzyme (ACE) 2, an important receptor in the pathogenesis of COVID-19, was demonstrated to be expressed in the thyroid tissues (22). Hence, the thyroid gland may be one of the targets damaged by SARS-CoV-2. Withal, the mechanism for this hypothesis remains unknown. Further investigation is necessary to determine whether ACE2 has an impact on the thyroid function in patients with COVID-19. Second, cytokine storms were very common in COVID-19 patients, especially in severe cases, characterized by the uncontrolled and excessive release of inflammatory mediators resulting in overwhelming systemic inflammation and even multiple organ dysfunction (23). In our research, the inflammatory responses seemed to be stronger in patients with ESS, with higher levels of CRP and erythrocyte sedimentation rate as well as a higher positive rate of procalcitonin. It is well known that cytokines are the key molecules involved in coordinating the hormone, immune, and inflammatory responses to stressful stimuli (24). In the previous study, patients admitted to the intensive care unit elicited lower serum concentrations of T4, FT4, T3, FT3, and TSH, while the serum levels of inflammatory cytokines including IL-1β and TNF-α were markedly elevated (25). The increase of inflammatory cytokines can result in suppression of central TSH and 5’-deiodinases activity. Third, our results indicated that ESS patients were more likely to have the symptom of fever compared with non-ESS patients. The invasion of SARS-CoV-2 causing hyperthermia can lead to down-regulation of 5’-deiodinases activity, resulting in decreases in T3 levels. Meanwhile, the disease related negative nitrogen balance and body consumption, can also lead to a decline in the serum levels of thyroid hormone transport proteins, inhibiting T4 transport in T3-producing tissues. Fourth, the effects of drugs on the thyroid function should not be ignored. Glucocorticoids and dopamine can inhibit the secretion of TSH by the pituitary and the intake of T4 by peripheral tissues. Likewise, amiodarone and beta-adrenergic blocking agents can suppress deiodinase activity and consequently T3 production, contributing to a decrease in serum T3 levels. Also, non-steroidal anti-inflammatory drugs (NSAIDs) are capable of transiently increasing free thyroid hormone levels by preventing their binding to plasma transport proteins (26). Given that the thyroid functions of our

![FIGURE 2](image-url)
patients were assessed on admission, further studies including the effects of drugs on the thyroid function are imperative to demonstrate the impact of COVID-19 pharmacotherapy on the development of ESS.

Our work above had some limitations. First, this study was a retrospective study, and the thyroid function was accessed only at admission. Second, the sample size was too small and only a few patients required the mechanical ventilation. Based on this fact, the assessment of the correlation between ESS and the ventilation requirement performed in this study may be biased. Third, the levels of gluocorticoid, rT3 and the pituitary function were unknown, which are needed to exclude the effects of other factors on the functions of various endocrine glands.

In summary, more than 25% COVID-19 patients were diagnosed with ESS in our research. ESS is an independent risk factor for the disease severity of COVID-19. COVID-19 patients with ESS had stronger inflammatory responses, with higher levels of CRP and erythrocyte sedimentation rate as well as a higher positive rate of procalcitonin. Further investigation with a large sample size and an appropriate study design are needed to demonstrate the impact of ESS in COVID-19 patients.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because: The data used in this paper are from public health treatment center, which can only be obtained with the approval of relevant institutions. Requests to access the datasets should be directed to YZ, zhongyanjun@csu.edu.cn.

REFERENCES

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol (2020) 92:401–2. doi: 10.1002/jmv.25678
2. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan. China Int J Infect Dis (2020) 91:264–6. doi: 10.1016/j.ijid.2020.01.009
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China: A descriptive study. Lancet (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
4. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (Accessed on August 28th, 2020).
5. Coronavirus disease 2019 (COVID-19) situation report 12. World Health Organization. (2020).
6. Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science (2020). doi: 10.1126/science.abc3208
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med (2020) 382:727–33. doi: 10.1056/NEJMoA200117
8. Wang W, Ye Y, Yao H, Li H, Sun L, Wang A, et al. Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome. J Clin Antituberculous Assoc (2003) 25:232–4.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by: The study was approved by the institutional ethics board of the Second Xiangya Hospital of Central South University (No. 20200001). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

RZ and CW were involved in study design, interpreting data, statistical analysis, creating tables and figures, and writing of the manuscript. SZ, GWa, QZ, BY, YW, and HD were involved in collecting data. YZ, SW, and GWu were involved in interpreting data, statistical analysis, and designed the research, supervised the work. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Emergency project for COVID-19 prevention and control of Central South University, China (No 160260005).

9. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev (2011) 32:670–93. doi: 10.1210/er.2011-0007
10. Lee S, Farwell AP. Euthyroid Sick Syndrome. Compr Physiol (2016) 6:1071–80. doi: 10.1002/cphy.c150017
11. Scoscia E, Baglioni S, Esami A, Iervasi G, Monti S, Todisco T. Low triiodothyronine (T3) state: a predictor of outcome in respiratory failure? Results of a clinical pilot study. Eur J Endocrinol (2004) 151:557–60. doi: 10.1530/eje.0.1510557
12. Bertoli A, Valentini A, Cianfarani MA, Gasbarra E, Tarantini U, Federici M. Low FT3: a possible marker of frailty in the elderly. Clin Interventions Aging (2017) 12:335–41. doi: 10.2147/CIA.S125934
13. National health commission. National administration of traditional Chinese medicine. Diagnosis and treatment of new coronavirus pneumonia (trial sixth edition). Chin J Viral Dis (2020) 10:1–5.
14. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. Open Forum Infect Dis (2020) 7:ofaa153. doi: 10.1093/ofid/ofaa153
15. Fu J, Huang PP, Zhang S, Yao QD, Han R, Liu HF, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med (2020) 20:3571–7. doi: 10.3892/etm.2020.9114
16. He F, Luo Q, Lei M, Fan L, Shao X, Huang G, et al. Risk factors for severe cases of COVID-19: a retrospective cohort study. Aging (Albany NY) (2020) 12:15730–40. doi: 10.18632/aging.103803
17. Zhou Y, Li B, Liu J, Chen D. The Predictive Effectiveness of Blood Biochemical Indexes for the Severity of COVID-19. Can J Infect Dis Med Microbiol (2020) 2020:7320813. doi: 10.1155/2020/7320813
18. Nomura R, Miyai K, Kuge R, Okura T, Goto M, Hasegawa Y. Free T3 to free T4 ratio less than 2.0 suggests low T3 syndrome rather than central
hypothyroidism from the age of two to eighteen years. *Endocr J* (2017) 64:213–9. doi: 10.1507/endocrj.EJ16-0169

19. Liu J, Wu X, Lu F, Zhao L, Shi L, Xu F. Low T3 syndrome is a strong predictor of poor outcomes in patients with community-acquired pneumonia. *Sci Rep* (2016) 6:22271. doi: 10.1038/srep22271

20. Lechan RM, Fekete C. Infundibular tanyctyes as modulators of neuroendocrine function: hypothetical role in the regulation of the thyroid and gonadal axis. *Acta Bio-Med Atenei Parmensis* (2007) 78 (Suppl 1):84–98.

21. Wei L, Sun S, Xu CH, Zhang J, Xu Y, Zhu H, et al. Pathology of the thyroid in severe acute respiratory syndrome. *Hum Pathol* (2007) 38:95–102. doi: 10.1016/j.humpath.2006.06.011

22. Narayan SS, Lorenz K, Ukkat J, Hoang-Vu C, Trojanowicz B. Angiotensins converting enzymes ACE and ACE2 in thyroid cancer progression. *Neoplasma* (2020) 67:402–9. doi: 10.4149/neop_2019_190506N405

23. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J Infect* (2020) 80:607–13. doi: 10.1016/j.jinf.2020.03.037

24. De Groot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. *Crit Care Clinics* (2006) 22:57–86. vi. doi: 10.1016/j.ccc.2005.10.001

25. Monig H, Arendt T, Meyer M, Kloehn S, Bewig B. Activation of the hypothalamic-pituitary-adrenal axis in response to septic or non-septic diseases—implications for the euthyroid sick syndrome. *Intens Care Med* (1999) 25:1402–6. doi: 10.1007/s001340051088

26. Burch HB. Drug Effects on the Thyroid. *N Engl J Med* (2019) 381:749–61. doi: 10.1056/NEJMr1901214

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.